Why are direct oral anticoagulants generally not used in cancer-associated thrombosis currently?

Why are direct oral anticoagulants generally not used in cancer-associated thrombosis currently?

• A. NOACs not studied in cancer patients yet
• B. They are less effective
• C. They are too expensive
• D. They require monitoring

Answer: (A)

The main idea here is that the historical choice of anticoagulant in cancer-associated thrombosis was driven by the evidence available, and for a long time direct oral anticoagulants had not been studied in cancer patients. Because randomized trials in cancer patients were lacking, clinicians relied on low-molecular-weight heparin, which had proven superiority over warfarin for preventing recurrent clots in this population. The lack of robust data meant there were uncertainties about how NOACs would perform in the setting of cancer, where chemotherapy, organ function changes, mucosal lesions, and potential drug interactions could affect efficacy and bleeding risk. This is why NOACs were not routinely used for cancer-associated thrombosis for many years. Although NOACs do not require routine monitoring and have practical advantages, those benefits could not be weighed against solid cancer-specific safety and efficacy data at the time. The other options don’t capture the historical reason: there wasn't a proven overall inferiority, cost alone, or a mandatory need for monitoring that prevented their use.

The main idea here is that the historical choice of anticoagulant in cancer-associated thrombosis was driven by the evidence available, and for a long time direct oral anticoagulants had not been studied in cancer patients. Because randomized trials in cancer patients were lacking, clinicians relied on low-molecular-weight heparin, which had proven superiority over warfarin for preventing recurrent clots in this population. The lack of robust data meant there were uncertainties about how NOACs would perform in the setting of cancer, where chemotherapy, organ function changes, mucosal lesions, and potential drug interactions could affect efficacy and bleeding risk. This is why NOACs were not routinely used for cancer-associated thrombosis for many years. Although NOACs do not require routine monitoring and have practical advantages, those benefits could not be weighed against solid cancer-specific safety and efficacy data at the time. The other options don’t capture the historical reason: there wasn't a proven overall inferiority, cost alone, or a mandatory need for monitoring that prevented their use.